Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab in HER2-overexpressing or Mutant Solid Cancers
NCT07192068Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in endometrial cancer (EC), colorectal cancer (CRC), head and neck cancer (HNC) and 2 more, sponsored by Unicancer. Primary endpoint: Objective Response Rate up to 28 months. Started Oct 2025; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
endometrial cancer (EC)colorectal cancer (CRC)head and neck cancer (HNC)sarcomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07192068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192068.